News
Dublin, OH (June 11, 2013) – Dr. Nancy Sawtell, a professor, and researcher at Cincinnati Children’s Hospital Medical Center, will be using technology developed by Biosortia Pharmaceuticals of Dublin, Ohio in collaboration to potentially discover new biologically active natural products for the treatment of infectious diseases. The drug discovery research is focused on the evaluation of
Continue ReadingMetabolites from Unculturable Microorganisms Create a Drug Discovery Opportunity Dublin, Ohio (May 22, 2013) – The Centre for Marine Bioactives and Drug Discovery (MabCent-SFI) at the University of Tromsø, Norway has entered into a collaborative relationship with Biosortia Pharmaceuticals of Dublin, Ohio to discover new biologically active natural products for the treatment of metabolic disorders. Research
Continue ReadingAuthor: Kelsey Kaustinen | Dublin, Ohio (April 2013) – The Ohio State University (OSU) and Biosortia Pharmaceuticals have found that a great industry partner can be just down the street. The two Dublin, Ohio-based organizations have established an agreement to discover new biologically active natural products that demonstrate potential anti-cancer activity. Biosortia will be sponsoring the
Continue ReadingRoss O. Youngs and Kurt Dieck of Biosortia Pharmaceuticals speak to a forum at CMC Dublin, Ohio (March 12, 2013) – With up to 20,000 species in a liter of water, the aquatic environment could become the next frontier for drug discovery. What is in the water is earning more respect thanks to a new biotech
Continue ReadingBiosortia Pharmaceuticals Creating Drug Discovery Opportunity with Previously Unstudied Microorganisms. Dublin, Ohio (February 26, 2013) – The Ohio State University has signed an agreement with Biosortia Pharmaceuticals of Dublin, Ohio to discover new biologically active natural products with potential anti-cancer activity. Potential candidate compounds discovered during the Biosortia-sponsored research project will primarily be tested against human
Continue ReadingDublin, Ohio (February 25, 2013) – On March 6th the Columbus Metropolitan Club at the Athletic Club of Columbus will host a lunch meeting where Biosortia Pharmaceuticals’ President & CEO Kurt Dieck along with founder Ross Youngs will share a look at the vast potential for a whole new world of biopharmaceutical drug discovery from aquatic
Continue ReadingRoss Youngs Founder of Biosortia Pharmaceuticals accepted a Proclamation as an Entrepreneurial representative that recognizes how vital entrepreneurship is to growth and prosperity from Timothy A. Lecklider, Mayor of Dublin Ohio. Recognition to Tech Columbus, the Dublin Entrepreneurial Center, and National Entrepreneurship Week was highlighted during the presentation. COMMENTS BY ROSS YOUNGS FOUNDER BIOSORTIA PHARMACEUTICALS
Continue ReadingBy Carrie Ghose, (February 1, 2013) – The same mystery toxins from blooms of algae that sicken swimmers and kill fish also might be the source of drugs to fight cancer or drug-resistant bacteria. Biosortia Pharmaceuticals, a subsidiary of Marysville-based Algaeventure Systems Inc., is prospecting wild waterways for rare and previously unidentified chemicals that could be
Continue ReadingBiosortia Pharmaceuticals, a Dublin-based subsidiary of Marysville-based Algaeventure Systems Inc. announced its CEO is Kurt Dieck Columbus, Ohio (January 28, 2013) – A startup prospecting mucky ponds for the pharmaceutical promise has hired two top executives with Fortune 100 experience. Biosortia Pharmaceuticals, a Dublin-based subsidiary of Marysville-based Algaeventure Systems Inc. announced its CEO is Kurt
Continue ReadingBiosortia Pharmaceuticals Hires Kurt Dieck as President and CEO to Accelerate Strategy to Develop and License New Highly Active Compounds from Unculturable Aquatic Microbial Consortia Dublin, Ohio (January 22, 2013) – Kurt Dieck formerly SVP of Strategy and Business Execution at Cardinal Health, will lead the early-stage drug discovery business at Biosortia Pharmaceuticals. Dieck was named
Continue Reading